Imiquimod 3.75% in actinic keratosis: efficacy in patients with and without rest periods during treatment
J Eur Acad Dermatol Venereol
.
2016 Aug;30(8):1416-7.
doi: 10.1111/jdv.13260.
Epub 2015 Aug 24.
Authors
T Dirschka
1
2
,
K Peris
3
,
G Gupta
4
,
A Alomar
5
,
S Aractingi
6
7
,
R Dakovic
8
,
E Stockfleth
9
Affiliations
1
Dermatological Practice Centre, Wuppertal, Germany.
2
Faculty of Health, University Witten-Herdecke, Witten, Germany.
3
Department of Dermatology, Catholic University of Rome, Largo A. Gemelli 8, 00168, Rome, Italy.
4
Department of Dermatology, Monklands Hospital, Airdrie, Lanarkshire, ML6 0JS, UK.
5
Department of Dermatology, Institut Universitari Quiron Dexeus, Av. Carles III 71-75, 8028, Barcelona, Spain.
6
Service de Dermatologie Allergologie, Hôpital Cochin, 89 rue d'Assas, 75006, Paris, France.
7
Université Paris 5 Descartes, Paris, France.
8
Meda Pharma GmbH & Co. KG, Benzstrasse 1, 61353, Bad Homburg, Germany.
9
Klinik für Dermatologie, Venerologie und Allergologie, St. Josef-Hospital, Ruhr-Universität Bochum, Bochum, Germany.
PMID:
26303677
DOI:
10.1111/jdv.13260
No abstract available
Publication types
Letter
Multicenter Study
MeSH terms
Aminoquinolines / administration & dosage
Aminoquinolines / therapeutic use*
Double-Blind Method
Drug Administration Schedule
Humans
Imiquimod
Keratosis, Actinic / drug therapy*
Substances
Aminoquinolines
Imiquimod